Pharma

The drug industry is pretty much coasting

WASHINGTON — Less than six months ago, President Trump stood at a podium and roiled the pharmaceutical industry with an emphatic declaration that its executives are “getting away with murder.”<p>If Congress has its way, the same president will soon sign into law a massive package that is at the top of …

How two common medications were combined into one $455-million specialty pill

Vimovo costs way more than the two individual medicines. So how have its manufacturers managed to make it sell?<p>Everything happened so fast as I …

Health Care

California activist Tom Steyer adds health care to his brand

Joining the drug price battle could boost the political fortunes of the California billionaire.<p>SAN FRANCISCO — California billionaire activist Tom Steyer made his name as an environmental activist, worked with Democratic groups to register a million new voters and redefined green politics with …

News

Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest

<b>Portola Pharmaceuticals</b>' (NASDAQ: PTLA) investors who stuck with it after stumbles caused share prices to crash last year are feeling a bit better about their position today. On Friday, the Food and Drug Administration approved the company's first drug, Bevyxxa, and that news caused shares to spike …

Stocks

How will the pharmaceutical industry evolve on drug pricing?

<b>HARI SREENIVASAN:</b> As the battle over health care rages in Congress, one constant complaint from consumers is over drug prices.<p>Judy Woodruff is in …

Health Care

3 Best Healthcare Dividend Stocks of the 21st Century (So Far)

Perhaps surprisingly, Aetna, Novo Nordisk, and West Pharmaceutical rank as the best healthcare dividend stocks of the century.<p>You have plenty of …

Stocks

Medical Marijuana Treatments by GW Pharmaceuticals

Make a list of the biotech and pharmaceutical companies developing marijuana-based, or cannabis, treatments, and GW Pharmaceuticals PLC (GWPH​) is …

Cannabis

Paulson Times Appointment to Valeant's Board Perfectly

John Paulson joined Valeant Pharmaceuticals board this week just as news reports broke suggesting drug price reforms coming out of Washington, D.C. …

Stocks

BRIEF-EMA recommends approval of Merck's multiple sclerosis drug

EU Medicines Agency:<p>* EU Medicines Agency recommendations for June 2017<p>* EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug<p>* EU Medicines Agency recommends approval of Abbvie Hepatitis C combination<p>* EU Medicines Agency recommends approval of Novartis Kisqali drug for …

World News

Samsung Makes Play for Drug Market With Version of Blockbuster Humira

A Samsung group arm is on track to win European regulatory approval for a near-replica version of the world’s top-selling drug, AbbVie Inc.’s rheumatoid-arthritis treatment Humira, the latest achievement by the deep-pocketed South Korean conglomerate attempting to shake up the pharmaceutical market.<p>…

U.S. Food and Drug Administration

Martin Shkreli fraud trial begins next week

Martin Shkreli, the former pharmaceutical executive who gained notoriety for hiking up the price of a life-saving drug, will finally go on trial next week on charges of ripping off investors.<p>Shkreli sparked outrage in 2015 for increasing the price of Daraprim, a drug used by AIDS patients, by more …

Business

Draft Drug Price Order Focuses on Regulations, Trade

Administration seeks faster drug approvals, promoting drug competition<p><b>BY ANDREW SIDDONS AND JOE WILLIAMS</b><p>The Trump administration might seek to roll …

FDA

Humira facing building pressure in EU as Samsung, Biogen get nod for biosimilar

A new flank is opening up in the assault on Humira, the world’s best-selling drug, as the European Medicines Agency today recommended approval of …

Drugmaker Astellas sanctioned for ‘shocking’ patient safety failures

Japanese drugmaker Astellas has been threatened with permanent expulsion from the UK’s pharmaceutical industry trade body after a series of …

The opioid epidemic and the pharmaceutical industry’s role (2 letters)

RJ Sangosti, Denver Post fileColorado Attorney General Cynthia Coffman is joining a bipartisan coalition of attorneys general across the country that …

Addiction

AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know

Could the world's best-selling drug have a protégé?<p>For years, <b>AbbVie</b>'s (NYSE:ABBV) powerhouse product Humira has held the top-dog position of …

Stocks

Supplement Wildly Unreliable, Despite FDA Regulations

Lots of people have an opinion on supplements. But when you go to the store to buy one, you’d expect the amount of the active ingredient to be …

Nutrition

Brainstorm Health Daily: June 23, 2017

Senate Republicans finally revealed their super-secret healthcare bill yesterday. And while it’s too early to count votes, I’m guessing that it won’t …

Affordable Care Act

FDA rejects Pfizer's Epogen biosimilar for a second time

Just a month after FDA staff and an advisory committee gave a ringing endorsement to Pfizer's biosimilar for Amgen's blockbuster Epogen, the agency …

Pfizer

Novartis breast cancer drug Kisqali wins European panel backing

ZURICH (Reuters) - A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.<p>The EMA's Committee for Medicinal Products for Human Use (CHMP) backed …

Cancer

Drug company criticised over 800pc price hike for narcolepsy treatment

The manufacturer of a drug described as "life-changing" for people with narcolepsy has been criticised for having some of the biggest price hikes …

Narcolepsy

One of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a Cure

NASH, a liver ailment, may affect more than 1 in 10 Americans but is often undetected. More than 40 drugs are in trials to treat it<p>The next frontier for multibillion-dollar drug therapies is a silent disease many people don’t know they have.<p>Dozens of pharmaceutical companies including Gilead …

Medicine

Regulatory Recon: FDA Rejects Pfizer Epogen Biosimilar Over Warned Manufacturing Site; Novartis, CSL Behring & Roche Pick Up US Approvals (23 June 2017)

<i>Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.</i><p>In Focus: US<p>Unpacking The Senate's Take On ACA Repeal And …

Regulation

FDA OKs Roche's new HIV combo assay

The FDA approves Roche's (OTCQX:RHHBY +1%) fourth-generation HIV combination antigen-antibody assay, Elecsys HIV combi PT. The qualitative test …

Medicine

How big brands are cashing in on hayfever sufferers charging 6 times over the odds - and how to beat them

Hayfever sufferers are being charged more than six times more for branded remedies that do an identical job to cheaper versions.<p>Drug giants ramp up …

Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use

ZUG, Switzerland--(BUSINESS WIRE)--The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a …

3 Biotech Stocks for Enterprising Investors

Kite Pharma, Celgene, and Acadia Pharmaceuticals are three biotech stocks that should be on enterprising investors' radars. Here's why.<p>Biotech stocks …

Stocks

Small-cap focus: UK’s booming biotech groups

Scientific leaps and tie-ups with big pharma are set to propel revenues to new heightsthem into a different league of revenue generation deliver far …

Medicine

CSL's Haegarda set for Q3 launch as Shire petitions for injunction

Even as it’s tangled in a rare disease patent dispute, CSL Behring has secured FDA approval for Haegarda to prevent HAE attacks in adolescents and …

Medicine

Idera's IMO-2125 an Orphan Drug in U.S. for advanced melanoma; shares ahead 5% premarket

Idera Pharmaceuticals (NASDAQ:IDRA) is up 5% premarket on average volume on the heels of its announcement that the FDA has designated Phase 2-stage …

United States